Hemp & Health as a Polish public company is traded on the Warsaw Stock Exchange (WSE:HMP) - click here.

 

STRATEGY OF HEMP & HEALTH S.A.
for 2024-2025

The strategy of HEMP & HEALTH S.A. ("Issuer" or "Company") is based on operating in complementary areas that lie at the intersection of two sectors: cannabis ("HEMP") and health ("HEALTH").
In the coming years, the Company plans to focus, within its Group of Companies ("CG"), on establishing and managing a full medical cannabis supply chain: from its own cultivation to the importation, processing and distribution of medical cannabis.

1 Own cultivation
The Company intends to become the Polish leader in the cultivation, either in-house or under contract, of medical cannabis containing more than 0.3% THC, i.e. so-called medical marijuana. Cultivation will be carried out through a special purpose company established for this purpose and/or investments in external entities. Such companies may be located both in Poland and abroad.

2 Pharmaceutical plant
A complementary link in the supply chain will be the launch of an in-house pharmaceutical plant, which will be able to confer EU-GMP1 to products that do not have this status - mainly of non-European origin. This type of service will also be able to be offered to non-GM and foreign entities as a subcontract. The pharmaceutical plant will have the ability to import, process, provide packaging services and EU GMP certification, as well as stability testing. As part of these services, the Issuer plans to sell products under its own brand, as well as in a private label or white label formula.

3 Distribution
The Company intends to distribute medical cannabis based on a pharmaceutical wholesaler belonging to the Group: THC Pharma SA. Such distribution may be based both on products registered in Poland by other entities and on the product registration obtained by the Issuer as MAH2. In this case, the product may originate both within and outside the European Union. The Issuer does not exclude the possibility of distribution outside Poland.

4. Research and development work
The Issuer takes into account the possibility of co-financing research to develop a cannabis-based medicine. This could take place in different modes (e.g. medical experimentation or drug development and clinical trials) conducted on behalf of the Issuer or as part of consortia. Research would include cannabis drugs based on both THC and CBD and other cannabinoids.

5. Activity within the HEMP and HEALTH segments
The Issuer does not rule out opportunistic investments in the cannabis or health industry that could increase and diversify revenues or provide synergies within the Group.

6. Abandonment of CBD distribution
At the current stage of EU regulations related to so-called 'novel food'1, the Company does not envisage distributing CBD products under its own brand and does not plan to engage in hemp cultivation containing less than 0.3% THC, i.e. targeting CBD.

7 Follow-up activities
The Company also plans to carry out the following activities over the coming two years:
1. acquire a strategic investor to implement the strategic objectives described above;
2. achieve registration as an MAH of a pharmaceutical raw material containing more than 0.3% THC, i.e. medical marijuana;
3. market medical cannabis in the form of dried and/or extracted products;
4. prepare the facilities and scalability of the business in the event of legalisation of recreational marijuana in Poland or in other European Union countries;
5. in the event of having surplus funds, allocate them to measures to counteract capital loss (e.g. due to inflation).

In the opinion of the Management Board, the updated and described above strategy of the Issuer will translate into dynamic development of the Company and increase of its value.

 

News

Zawarcie listu intencyjnego dotyczącego przeprowadzenia negocjacji dotyczących nabycia plantacji m…

Added: 22.01.2024

W dniu dzisiejszym Zarząd zawarł list intencyjny dotyczący prowadzenia negocjacji zmierzających do uzgodnienia zasad nabycia przez Emitenta całości, części lub zorganizowanej części przedsiębiorstwa na terytorium Czech - w pełni wyposażonego... Read more

Podpisanie Term Sheet dotyczącego istotnego dokapitalizowania Emitenta.

Added: 16.11.2023

Zarząd Hemp_Health S.A. informuje, że w dniu 16/11/2023 uzgodnił Warunki Umowy "Term Sheet" z inwestorem - podmiotem zagranicznym, dotyczące warunków emisji warrantów subskrypcyjnych uprawniających do objęcia akcji Emitenta ("Transakcja").W ramach... Read more

Złożenie wniosku o wydanie zezwolenia na obrót hurtowy środkami odurzającymi i substancjami psy…

Added: 13.11.2023

Zarząd spółki stowarzyszonej, tj. THC Pharma S.A. ("THC Pharma") złożył w Głównym Inspektoracie Farmaceutycznym ("GIF") wniosek o wydanie zezwolenia na obrót hurtowy środkami odurzającymi i substancjami psychotropowymi z grupy I-N... Read more

Możliwość istotnego dokapitalizowania Emitenta oraz zawarcie listu intencyjnego.

Added: 09.11.2023

W dniu 09/11/2023 roku Emitent zawarł List Intencyjny z inwestorem - podmiotem zagranicznym, dotyczący warunków emisji warrantów subskrypcyjnych uprawniających do objęcia akcji Emitenta (Transakcja).Strony ustaliły, iż negocjacje rozpoczną się niezwłocznie... Read more

Strategia Spółki na lata 2024-2025

Added: 08.11.2023

Zarząd Hemp & Health S.A. prezentuje strategię rozwoju Spółki na lata 2024-2025. W nadchodzących latach Spółka planuje w ramach swojej Grupy Kapitałowej (GK) skoncentrować się na stworzeniu i zarządzaniu pełnym łańcuchem... Read more

Rezygnacja z nabycia udziałów w podmiocie prowadzącym hurtownię farmaceutyczną

Added: 04.11.2023

Zarząd podjął decyzję o rezygnacji z nabycia udziałów w podmiocie prowadzącym hurtownię farmaceutyczną. Decyzja wynika z faktu uzyskania zezwolenia na prowadzenie hurtowni farmaceutycznej przez THC Pharma S.A., to jest spółkę... Read more

If you have any question? Call +48 22 487 83 68

Contact

Hemp & Health S.A.
Krakowskie Przedmieście 13
00-071 Warsaw
Poland

Telephone: +48 22 487 83 68

Registration Number (KRS): 0000396780
VAT: 5252382713

NCAGE: 9A59H
DUNS: 522357524

 

 

Contact form

Form by ChronoForms - ChronoEngine.com

© 2023 All rights reserved Hemp & Health S.A.